NCT01616875 2026-03-06
Bristol Bladder Trial
University Hospitals Bristol and Weston NHS Foundation Trust
Phase 2 Completed
Clinical Trials
46 trialsNCT05701007 2026-01-29
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Completed
NCT03556904 2026-01-15
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT02985957 2025-12-22
CheckMate 650
Bristol-Myers Squibb
Phase 2 Completed
NCT05005728 2025-07-17
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Xencor, Inc.
Phase 2 Completed
NCT01420250 2025-05-15
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
Thomas Jefferson University
Phase 1 Completed
NCT02218606 2024-12-10
Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02903160 2024-02-07
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT02543255 2024-01-31
ACDC-RP
University Health Network, Toronto
Phase 2 Completed
NCT04495179 2023-08-09
AARDVARC
AstraZeneca
Phase 2 Completed
NCT03114254 2022-11-18
JAVA-P
University Hospitals Bristol and Weston NHS Foundation Trust
Phase 2 Completed
NCT05471427 2022-07-22
ANCHISES
Azienda Ospedaliero-Universitaria Careggi
Completed
NCT03392428 2022-06-13
TheraP
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Completed
NCT02485691 2022-05-27
CARD
Sanofi
Phase 4 Completed
NCT02961257 2022-05-12
CABASTY
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 3 Completed
NCT03295565 2022-04-15
OSTRICh
The Netherlands Cancer Institute
Phase 2/3 Completed
NCT03101046 2022-02-10
TACTIK
UNICANCER
Phase 2 Completed
NCT01913652 2021-09-14
Ph II Cabazitaxel DD Liposarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT01620242 2021-03-02
ORL03
UNICANCER
Phase 2 Completed
NCT03419442 2020-10-22
Multi-academic Center Study of Xofigo Patients
Bayer
Completed
NCT02560337 2020-10-08
CaTo-ROC
Vejle Hospital
Phase 2 Completed
NCT02512458 2020-02-10
CABA-BONE
Hellenic Cooperative Oncology Group
Phase 2 Completed
NCT01308567 2019-06-05
FIRSTANA
Sanofi
Phase 3 Completed
NCT01668459 2018-12-04
CabB1
University Hospital Birmingham NHS Foundation Trust
Phase 2/3 Completed
NCT01956149 2018-04-18
Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT01757171 2018-04-03
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Weill Medical College of Cornell University
Phase 2 Completed
NCT01718353 2017-11-20
TAXYNERGY
Sanofi
Phase 2 Completed
NCT01866449 2017-10-26
Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme
University of Ulm
Phase 2 Completed
NCT01693549 2017-08-01
Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes
Hellenic Cooperative Oncology Group
Phase 2 Completed
NCT01594918 2017-07-21
Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Completed
NCT01528163 2017-06-14
RACATREX
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Completed
NCT01308580 2017-04-17
PROSELICA
Sanofi
Phase 3 Completed
NCT02441894 2017-01-24
PEGAZUS
Sanofi
Phase 4 Completed
NCT01578655 2016-10-12
AFFINITY
Achieve Life Sciences
Phase 3 Completed
NCT01447225 2016-09-14
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
Merrimack Pharmaceuticals
Phase 1 Completed
NCT01751308 2016-08-12
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Sanofi
Phase 1/2 Completed
NCT01541007 2015-11-02
ConCab
Karolinska University Hospital
Phase 2 Completed
NCT01852578 2015-09-28
Cabazitaxel in Relapsed and Metastatic NSCLC
Hellenic Oncology Research Group
Phase 2 Completed
NCT01140607 2015-07-21
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Sanofi
Phase 1 Completed
NCT01600339 2015-05-12
A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC)
Rambam Health Care Campus
Phase 2 Completed
NCT01379339 2015-02-11
Cabazitaxel - PF Induction Chemotherapy
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT01254279 2015-01-21
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
Sanofi
Phase 3 Completed
NCT01576029 2013-12-24
SWITCH
Sanofi
Phase 2 Completed
NCT00925743 2013-05-16
A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer
Sanofi
Phase 1 Completed
NCT01755390 2012-12-24
A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT01087021 2011-12-16
QT-Cab
Sanofi
Phase 1 Completed